Title
Category
Credits
Event date
Cost
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Click here for activity.
  • Gastrointestinal
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Please Note: Credit Is No Longer Available The implementation of molecular testing, especially analysis of human epidermal growth factor receptor 2 (HER2) status, has had a significant impact on clinical practice and patient care. Join Drs. David Ilson and Michael Press for this on-demand online activity, as they discuss assessment of HER2-mutant disease from each of their unique perspectives.Supported through an independent educational grant from AstraZeneca and Daiichi Sankyo. 
  • Oncology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Please Note: Credit Is No Longer Available As the treatment paradigm for bladder cancer continuously evolves, all members of the oncology healthcare team must be equipped to evolve with it to ensure optimal patient care. With this evolution comes many questions for the bladder cancer treatment team. Join Drs. Neal Shore, Arjun Balar, Lidia Lopez, and Nurse Joanie Pfahl as they examine the new paradigm of bladder treatment using ICIs, and discuss the important role of each person on the treatment team.
  • Gastrointestinal
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Please Note: Credit Is No Longer Available 
  • Oncology
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Please Note: Credit Is No Longer Available 
  • Oncology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Please Note: Credit Is No Longer Available 
  • Oncology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Please Note: Credit Is No Longer Available 
  • Gastrointestinal
  • Oncology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Please Note: Credit Is No Longer AvailableAntibody-drug conjugates or “ADCs” are a novel class of highly potent biopharmaceutical drug composed of an antibody linked, via a chemical linker, to a biologically active drug or cytotoxic compound. Nearly 150 investigational ADCs are currently in pre-clinical and clinical trials. Join Drs. David Ilson and Kohei Shitara as they discuss emerging data from select clinical trials evaluating combinations of HER2-targeted therapies for patients with gastric cancer.
  • Oncology
  • Pulmonology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Please Note: Credit Is No Longer Available Medical Moment One: Expert Insight on Practical Aspects of Molecular Profiling for Early-Stage NSCLC Cancers 
  • Oncology
  • Pulmonology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Please Note: Credit Is No Longer Available Medical Moment Two: Expert Insight on Applying the ADAURA Results to Treatment of Early-Stage NSCLC Patients 

Pages